Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.95 +0.00 (+0.04%)
As of: Sep 30, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015)

Updated

Lineage Cell Therapeutics (LCTX) reported Preferred Shares of $3.5 million for Q2 2015, unchanged from $3.5 million a year earlier and unchanged from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015) Analysis & Trends

Dating back to Q1 2014, Lineage Cell Therapeutics' Preferred Shares record includes 6 quarters.

  • Per Business Quant data, the three quarters before Q2 2015 came in at $3.5 million (Q1 2015), $3.5 million (Q4 2014) and $3.5 million (Q3 2014).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Lineage Cell Therapeutics 242.79 Mn 41.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 3.50 Mn
Mar 31, 2015 3.50 Mn
Dec 31, 2014 3.50 Mn
Sep 30, 2014 3.50 Mn
Jun 30, 2014 3.50 Mn
Mar 31, 2014 3.50 Mn
API Access

Lineage Cell Therapeutics Preferred Shares API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-shares&ticker=LCTX&period=max&api_key=YOUR_API_KEY